NFE2L2 and cancer: Nevertheless, we took this potential cancer-promoting risk of Nrf2 activation by DMF into account during the design of our trial, and, to avoid any risk of cancer aggravation, participants with a history of malignancy that would compromise the 2-year study survival or with history of cancer diagnosed within the past five years that could be worsened by immunosuppression have been specifically excluded.